SETD1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Molibresib (SCHEMBL1872390)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
SCHEMBL9998851	0.91	1/20
SCHEMBL14756282	0.88	1/20
SCHEMBL15980874	0.88	1/20
SCHEMBL12966165	0.87	1/20
SCHEMBL14756215	0.87	1/20
SCHEMBL14756339	0.87	1/20
SCHEMBL15980861	0.87	1/20
SCHEMBL9998825	0.86	1/20
SCHEMBL15980893	0.86	1/20
SCHEMBL15980803	0.86	1/20
SCHEMBL1874116	0.85	1/20
SCHEMBL12671221	0.85	1/20
SCHEMBL14756021	0.85	1/20
SCHEMBL14756240	0.85	1/20
SCHEMBL14756287	0.85	1/20
SCHEMBL14756335	0.85	1/20
SCHEMBL14756409	0.85	1/20

Clinical trials — most relevant to SETD1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML	PHASE3	UNKNOWN
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	PHASE2	ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	PHASE2	RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
The Efficacy of Allo-HSCT in ND HR-CBF-AML	nan	RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
Mechanisms of Immune Deficiency	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)	nan	NO_LONGER_AVAILABLE
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Clinical and Genomic Registry of MDS in Asia	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Impact of Air Quality on the Effectiveness of Standard of Care Therapy in Children With Autism Spectrum Disorder: A Prospective Longitudinal Study	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SETD1A binder may also engage these)

Protein	Name	Similarity
E9PYH6	—	1.000	E9PYH6 →
Q66J90	—	1.000	Q66J90 →
Q8CFT2	—	1.000	Q8CFT2 →
SETD1B	Histone-lysine N-methyltransferase SETD1B	0.999	landscape →
P14653	—	0.998	P14653 →
A2D4R4	—	0.998	A2D4R4 →
TET3	Methylcytosine dioxygenase TET3	0.997	landscape →
A2T7J2	—	0.997	A2T7J2 →
A2T6H5	—	0.997	A2T6H5 →
A1YG01	—	0.996	A1YG01 →
PRRC2A	Protein PRRC2A	0.996	landscape →
Q80WT2	—	0.996	Q80WT2 →
O95886	—	0.996	O95886 →
Q9R0L7	—	0.996	Q9R0L7 →
Q9P1Z0	—	0.996	Q9P1Z0 →
Q8C3W1	—	0.996	Q8C3W1 →
P48435	—	0.995	P48435 →
Q08D57	—	0.995	Q08D57 →
P97838	—	0.995	P97838 →
A2D649	—	0.995	A2D649 →
PPHLN1	Periphilin-1	0.995	landscape →
Q5TM26	—	0.995	Q5TM26 →
Q5VZP5	—	0.995	Q5VZP5 →
Q04888	—	0.995	Q04888 →
Q9ER75	—	0.995	Q9ER75 →
Q6PFD5	—	0.995	Q6PFD5 →
P19091	—	0.995	P19091 →
Q9P1A6	—	0.995	Q9P1A6 →
KDM3B	Lysine-specific demethylase 3B	0.995	landscape →
AKAP8L	A-kinase anchor protein 8-like	0.995	landscape →